Liver Disease Clinical Trials in San Antonio, TX

46 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH	Phase 3	GlaxoSmithKline	<1 mi
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)	Phase 2	Eccogene	<1 mi
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein	Phase 3	Takeda	<1 mi
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics	Phase 1	PharmaIN	<1 mi
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH	Phase 3	89bio, Inc.	<1 mi
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment	Phase 1	GlaxoSmithKline	<1 mi
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH	Phase 3	Akero Therapeutics, Inc	<1 mi
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease	Phase 2	GlaxoSmithKline	<1 mi
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis	Phase 3	Ipsen	<1 mi
Evaluation of Non-Invasive Tests for Metabolic Liver Disease	—	Foundation for the National Institutes of Health	<1 mi
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)	Phase 2	Boehringer Ingelheim	<1 mi
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)	Phase 3	Takeda	<1 mi
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)	Phase 3	89bio, Inc.	<1 mi
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function	Phase 1	Eli Lilly and Company	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.	Phase 1	Eli Lilly and Company	<1 mi
Evaluating the Pharmacokinetics and Safety of Miricorilant	Phase 1	Corcept Therapeutics	<1 mi
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis	Phase 3	Gilead Sciences	<1 mi
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH	Phase 3	GlaxoSmithKline	<1 mi
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support	Phase 2/3	Protara Therapeutics	<1 mi
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome	Phase 3	Albireo, an Ipsen Company	<1 mi
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition	Phase 2	Regeneron Pharmaceuticals	<1 mi
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis	Phase 3	Boehringer Ingelheim	<1 mi
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function	Phase 1	X4 Pharmaceuticals	<1 mi
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection	Phase 2	Gilead Sciences	<1 mi
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight	Phase 2	Amgen	<1 mi
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	Phase 3	Eli Lilly and Company	<1 mi
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis	Phase 3	Boehringer Ingelheim	<1 mi
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)	Phase 2	Altimmune, Inc.	<1 mi
Quantifying Hepatic Mitochondrial Fluxes in Humans	Phase 4	The University of Texas Health Science Center at San Antonio	<1 mi
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection	Phase 1	GigaGen, Inc.	<1 mi
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis	Phase 2	AstraZeneca	<1 mi
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors	Phase 1/2	ModeX Therapeutics, An OPKO Health Company	<1 mi
FOG-001 in Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Parabilis Medicines, Inc.	<1 mi
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)	Phase 2	Anwaar Saeed	<1 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment	—	Fresenius Kabi	<1 mi
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma	Phase 1	Alnylam Pharmaceuticals	<1 mi
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma	Phase 1	Nammi Therapeutics Inc	<1 mi
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	Phase 1/2	Tvardi Therapeutics, Incorporated	<1 mi
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma	—	The University of Texas Health Science Center at San Antonio	<1 mi
IDOV-Immune for Advanced Solid Tumors	Phase 1	ViroMissile, Inc.	<1 mi
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis	Phase 2	The University of Texas Health Science Center at San Antonio	<1 mi
A Study of ZW251 in Participants With Advanced Solid Tumors	Phase 1	Zymeworks BC Inc.	<1 mi
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment	Phase 1	Gilead Sciences	<1 mi
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors	Phase 1	Angiex, Inc.	<1 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	Phase 3	AstraZeneca	<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.